- Policy
- HIRA starts preparing for RWE-based reimb reevaluations
- by Lee, Tak-Sun Nov 29, 2023 05:50am
- The Health Insurance Review and Assessment Service are accelerating the establishment of a plan to reevaluate Korea’s reimbursed drugs based on RWD (Real World Data)/RWE (Real World Evidence). The idea of RWD/RWE-based reimbursement reevaluations took shape at the public hearing for the ‘Performance-based reimbursement management plan
- Policy
- DPM Choo ‘will finalize telemedicine plans this year'
- by Kang, Shin-Kook Nov 28, 2023 05:42am
- The direction of the government's policy to institutionalize non-face-to-face treatment has been set to institutionalize non-face-to-face treatment for overseas Korean nationals and prepare an improvement plan for the domestic non-face-to-face treatment pilot project within the year. Deputy Prime Minister Kyung-Ho Choo presided over the Emerg
- Policy
- Enspryng and Jemperli will be reimbursed through RSA
- by Lee, Tak-Sun Nov 22, 2023 05:30am
- The new Neuromyelitis optica spectrum disorder (NMOSD) drug Enspryng Prefilled Syringe Inj (satralizumab, Roche) and new PD-1 inhibitor immune-oncology drug ‘Jemperli Inj (dostarlimab, GSK) will be reimbursed in Korea from December 1st this year. Also, the insurance price ceiling for Xeljanz Tab 5mg, for which reimbursement has been exte
- Policy
- Will PE exemption drugs be reevaluated based on RWD?
- by Lee, Tak-Sun Nov 22, 2023 05:30am
- Will ultra-high-priced drugs or drugs exempted from receiving pharmacoeconomic evaluations be reevaluated based on actual patient administration data after being listed for reimbursement? Starting with Kymriah first last year, as drugs were applied a performance-based refund type RSA for reimbursement, an interpretation that it would no
- Policy
- Global bioleaders gather in Seoul for World Bio Summit
- by Lee, Jeong-Hwan Nov 21, 2023 05:48am
- Vaccine and bio leaders from around the world will gather in Seoul, Korea to discuss response strategies for the next global pandemic that may come after COVID-19. On the 19th, the Ministry of Health and Welfare and the World Health Organization (WHO) announced they will hold the '2023 World Bio Summit' from the 20th to the 21st at the Conrad
- Policy
- Results of the 2nd price ceiling reevals to be released soon
- by Lee, Tak-Sun Nov 20, 2023 05:50am
- The National Health Insurance Service plans to hold a preliminary briefing session before starting its main negotiations for the 2nd drug price ceiling re-evaluations. The authorities decided upon this measure to inform companies in advance about the documents that would need to be submitted for negotiations due to the tight 10-day neg
- Policy
- Takeda Obizur accepts results of the drug rating
- by Lee, Tak-Sun Nov 17, 2023 05:59am
- If the alternative drug was accepted less than 90%, the drug price negotiation was omitted. It was confirmed which was conditionally approved by the Pharmaceutical benefit evaluation committee in October, accepted the results and moved to the stage of negotiation. This drug is used to treat bleeding in patients with adult acquired hemoph
- Policy
- Abbvie’s Skyrizi is approved for Crohn's disease in Korea
- by Lee, Hye-Kyung Nov 16, 2023 05:46am
- Abbvie’s ‘Skyrizi,’ which was first introduced to Korea as a psoriasis treatment, has received additional marketing authorization for its Crohn's disease indication The Ministry of Drug and Safety approved Abbvie Korea’s ‘Skyrizi Inj (risankizumab)’ and ‘Skyrizi Cartridge Inj (risankizumab)’ on the 15th. The products, which contain
- Policy
- Chinese immunotherapy tislelizumab to soon arrive in KOR
- by Lee, Hye-Kyung Nov 15, 2023 05:39am
- A PD-1 cancer immunotherapy developed in China is soon expected to receive marketing approval in Korea. According to industry sources on the 14th, the Ministry of Food and Drug Safety has completed the drug safety and efficacy review for BeiGene Korea’s ‘Tevimbra 100mg (tislelizumab).’ If no issues were found during the safety and effi
- Policy
- Drug price lawsuit recovery & refund, effective on the 20th
- by Lee, Jeong-Hwan Nov 15, 2023 05:39am
- Pharmaceutical company to reduce drug price, abusing lawsuit to reduce 'term profit' strategy In order to recover or refund the loss of drug costs as a result of the drug price-down lawsuit, the NHIS must notify the pharmaceutical company of the details such as the amount of refund, method, and the deadline for submitting opinions. The C
